Foundayo, a new obesity treatment from Eli Lilly, has been recommended for approval in Europe, offering an easy-to-use oral alternative to injectable weight loss drugs.
New obesity drug gets approval recommendation
On 15 October 2026, the human medicines committee of the European Medicines Agency recommended approval for Foundayo, a drug developed by Eli Lilly. This medication is intended for treating obesity and type 2 diabetes and comes in tablet form. Foundayo’s mechanism and benefits
Foundayo contains orforglipron, a molecule that mimics the action of an intestinal hormone involved in regulating appetite. Its main advantage is ease of use, as it can be taken without specific meal-related constraints. Next steps for approval and availability
The European Medicines Agency’s recommendation paves the way for commercialization, though the European Commission must still confirm approval in the coming weeks. Foundayo is designed for adults with obesity or overweight accompanied by a complication, as well as for some diabetics. Global availability and market impact
Lilly has already requested approval for Foundayo in more than forty countries, and the tablet is already available in the United States since April 2026. This shift to an oral format could significantly increase the number of people treated, as previous weight loss treatments required injections. Orforglipron’s classification
Orforglipron belongs to the family of glucagon-like peptide-1 receptor agonists, a class of drugs known for their role in regulating blood sugar and appetite.
